

Use of Colistin and Other Critical Antimicrobials on Pig and Chicken Farms in Southern Vietnam and Its Association with Resistance in Commensal *Escherichia coli* Bacteria

Nhung T. Nguyen,^a Hoa M. Nguyen,^a Cuong V. Nguyen,^a Trung V. Nguyen,^{a,b} Men T. Nguyen,^c Hieu Q. Thai,^c Mai H. Ho,^c Guy Thwaites,^{a,d} Hoa T. Ngo,^{a,d} Stephen Baker,^{a,d} Juan Carrique-Mas^{a,d}

Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam^a; Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands^b; Sub-Department of Animal Health, My Tho, Tien Giang Province, Vietnam^c; Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, Oxford University, Oxford, United Kingdom^d

ABSTRACT

Antimicrobial resistance (AMR) is a global health problem, and emerging semi-intensive farming systems in Southeast Asia are major contributors to the AMR burden. We accessed 12 pig and chicken farms at key stages of production in Tien Giang Province, Vietnam, to measure antimicrobial usage and to investigate the prevalence of AMR to five critical antimicrobials (β -lactams, third-generation cephalosporins, quinolones, aminoglycosides, and polymyxins) and their corresponding molecular mechanisms among 180 *Escherichia coli* isolates. Overall, 94.7 mg (interquartile range [IQR], 65.3 to 151.1) and 563.6 mg (IQR, 398.9 to 943.6) of antimicrobials was used to produce 1 kg (live weight) of chicken and pig, respectively. A median of 3 (out of 8) critical antimicrobials were used on pig farms. *E. coli* isolates exhibited a high prevalence of resistance to ampicillin (97.8% and 94.4% for chickens and pigs, respectively), ciprofloxacin (73.3% and 21.1%), gentamicin (42.2% and 35.6%), and colistin (22.2% and 24.4%). The prevalence of a recently discovered colistin resistance gene, *mcr-1*, was 19 to 22% and had strong agreement with phenotypic colistin resistance. We conducted plasmid conjugation experiments with 37 *mcr-1* gene-positive *E. coli* isolates and successfully observed transfer of the gene in 54.0% of isolates through a plasmid of approximately 63 kb, consistent with one recently identified in China. We found no significant correlation between total use of antimicrobials at the farm level and AMR. These data provide additional insight into the role of *mcr-1* in colistin resistance on farms and outline the dynamics of phenotypic and genotypic AMR in semi-intensive farming systems in Vietnam.

IMPORTANCE

Our study provides accurate baseline information on levels of antimicrobial use, as well as on the dynamics of phenotypic and genotypic resistance for antimicrobials of critical importance among *E. coli* over the different stages of production in emerging pig and poultry production systems in Vietnam. *E. coli* isolates showed a high prevalence of resistance (>20%) to critically important antimicrobials, such as colistin, ciprofloxacin, and gentamicin. The underlying genetic mechanisms identified for colistin (the *mcr-1* gene) and quinolone (*gyrA* gene mutations) are likely to play a major role in AMR to those compounds. Conjugation experiments led to the identification of a 63-kb plasmid, similar to one recently identified in China, as the potential carrier of the *mcr-1* gene. These results should encourage greater restrictions of such antimicrobials in Southeast Asian farming systems.

Antimicrobials are widely used in animal production to prevent and treat disease and to improve growth performance (1). Nearly all antimicrobial classes important for human medicine are also used in animal production (2). The association between antimicrobial use (AMU) and resistance (AMR) in commensal bacteria on poultry and pig farms has been established (3, 4). However, most studies to date have been conducted in the intensive-production systems prevalent in developed countries. In contrast, few data are available from semi-intensive systems prevalent in developing countries, where farmers typically have little access to veterinary support.

Of particular concern is the prevalent use of antimicrobials considered by the World Health Organization (WHO) to be of critical importance for human medicine (5) in Vietnamese pig and poultry farms. These antimicrobials include penicillins, third-generation cephalosporins, quinolones, aminoglycosides, polymyxins, and macrolides (6–8).

Escherichia coli is a commensal organism of the gastrointestinal tract and a widely used marker to monitor AMR in livestock and

meat (9, 10). Although a high prevalence of AMR among *E. coli* strains has been reported on animal farms in Vietnam (7, 11), little is known about the molecular mechanisms of resistance. In *E. coli*, reduced susceptibility and resistance to quinolones are known to be associated with mutations in the DNA gyrase gene (*gyrA*) (12)

Received 1 February 2016 Accepted 8 April 2016

Accepted manuscript posted online 15 April 2016

Citation Nguyen NT, Nguyen HM, Nguyen CV, Nguyen TV, Nguyen MT, Thai HQ, Ho MH, Thwaites G, Ngo HT, Baker S, Carrique-Mas J. 2016. Use of colistin and other critical antimicrobials on pig and chicken farms in southern Vietnam and its association with resistance in commensal *Escherichia coli* bacteria. *Appl Environ Microbiol* 82:3727–3735. doi:10.1128/AEM.00337-16.

Editor: C. A. Elkins, FDA Center for Food Safety and Applied Nutrition

Address correspondence to Nhung T. Nguyen, nhungnt@oucr.uo.

Copyright © 2016 Nguyen et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

and/or the presence of plasmid-mediated quinolone resistance (PMQR) determinants, including the Qnr proteins, the acetylating AAC(6′)-Ib-cr enzyme, and QepA efflux pumps (13). Common aminoglycoside resistance mechanisms among *Enterobacteriaceae* include expression of adenyltransferases and phosphoryltransferases encoded by *aadA* and *strA-strB*, respectively, which are located within multidrug resistance (MDR) integrons (14). Very recently, plasmid-mediated colistin resistance, encoded by the *mcr-1* gene, was discovered in *E. coli* isolates from pigs, chickens, and humans in China. In view of the higher prevalence of positive samples in animal isolates, it is likely that the *mcr-1* resistance mechanism originated in animals and subsequently spread to humans (15).

In this study, we aimed (i) to measure levels of antimicrobial use and AMR and to assess the prevalence of a selection of nine AMR-associated genes encoding resistance to antimicrobials that are commonly used in human health care among commensal *E. coli* at different stages of production and (ii) to investigate the relationship between phenotypic and genotypic markers of resistance and between AMU and AMR. To address these aims, we conducted a longitudinal study during the production cycle on 12 pig and meat chicken farms typical of emerging semi-intensive systems in the Mekong Delta region of Vietnam.

MATERIALS AND METHODS

Selection of study farms. A total of six chicken (C1 to C6) and six pig (P1 to P6) units representative of emerging semi-industrial production farming systems in the Mekong Delta region of Vietnam were studied. The selected chicken farms met the following criteria: (i) they raised chickens for meat production, (ii) they had between 500 and 10,000 chickens, and (iii) they performed all-in/all-out management (i.e., all chickens were bought and sold at the same time). The selected pig farms met the following criteria: (i) they raised pigs from farrowing to slaughter at any one time on the farm and (ii) they had at least 50 pigs at one any time on the farm.

Farm sampling. From each farm, rectal/cloacal swabs were collected from chickens and pigs on three consecutive visits: (i) the day of arrival of chicks from the hatchery (chickens) or 1 to 2 days after farrowing (pigs), (ii) midproduction (chickens, 25 to 30 days old; pigs, 60 to 65 days old); and (iii) immediately before sale (chickens, 45 to 48 days old; pigs, 125 to 130 days old). On the first visit to each farm, 10 randomly selected animals were tagged using leg rings (chickens) or ear notches (pigs). The same animals were sampled on subsequent visits.

Data collection. Data on administration of antimicrobials by the farmer and in feed were collected during the farm visits using questionnaires. Data on AMU was defined for two distinct periods: (i) between restocking/birth and the second sampling and (ii) between the second and third samplings. Visits were conducted between November 2013 and June 2014 by trained veterinarians affiliated with the Tien Giang Sub-Department of Animal Health (SDAH).

Isolation of *E. coli*. The rectal/cloacal swabs collected on each visit from the target animals were pooled and tested as one analytical sample. In order to isolate *E. coli*, samples were streaked directly onto MacConkey agar (Oxoid, United Kingdom) and were subsequently incubated at 37°C overnight. Up to five colonies showing typical *E. coli* morphology were confirmed using standard biochemical tests (motility, indole, lactose/glucose fermentation, methyl red, citrate, urease, hydrogen sulfide, and gas production).

Phenotypic testing of AMR. Colonies confirmed as *E. coli* were phenotypically tested for their susceptibility to ampicillin (10 µg) and ceftazidime (30 µg) (Oxoid, United Kingdom) by the Kirby-Bauer disk diffusion test. Ciprofloxacin, gentamicin, and colistin resistance was investigated by determining the MIC using Etest (bioMérieux, France). The reference strain *E. coli* ATCC 25922 was used for quality control

purposes. In order to establish the susceptibility status of test strains, the guidelines on breakpoints provided by the Clinical and Laboratory Standards Institute (16) were followed. The strains were considered to have colistin resistance if their MICs were >2 µg/ml, as described by the European Committee on Antimicrobial Susceptibility Testing (17). Colonies that were intermediate in resistance based on the inhibition zone were also regarded as resistant. An MDR organism was defined as a strain that is resistant to at least three different antimicrobial classes.

PCR amplification of AMR genes and DNA sequencing. Rapid DNA preparation was performed by a boiling technique that included a heating step (95°C for 15 min) for colonies in a total volume of 200 µl of distilled water, followed by a centrifugation step for the cell suspension. PCR amplification of the quinolone [*qnrA*, *qnrB*, *qnrS*, *qepA*, *aac(6′)-Ib-cr*, and *gyrA*], aminoglycoside (*aadA* and *strA-strB*), and colistin resistance (*mcr-1*) genes was performed using previously published primer sets (15, 18–20). PCR amplification was performed using a Tprofessional Thermocycler (Biometra, Germany) and BioTaq polymerase (Bioline, United Kingdom). PCR amplicons were examined by electrophoresis and UV visualization on 1.5% agarose gels containing Nancy fluorescent stain (Sigma, Germany). Amplicons produced from all the strains specific for *gyrA* were sequenced with the same primers used for amplification. The forward and reverse strands of all PCR products were sequenced using BigDye terminators on an ABI sequencer (Life Technologies, USA).

Plasmid conjugation experiment. The potential transmissibility of the *mcr-1* gene was investigated by performing an *mcr-1*-containing-plasmid conjugation experiment. We independently mated an *mcr-1* plasmid-containing strain (donor) with pansusceptible sodium azide-resistant *E. coli* J53 (recipient). The bacteria were conjugated for 12 h in Luria-Bertani (LB) broth at 37°C, and transconjugant strains were selected on LB agar plates supplemented with colistin (2 mg/liter) and sodium azide (100 mg/liter). The colonies on each plate were counted, and the number was used to estimate the transfer frequency per donor in successful transfer experiments. Plasmids were extracted from the donors and transconjugants using the method described by Kado and Liu (21). DNA was separated on 0.7% agarose gels and visualized under UV light after staining with ethidium bromide. The approximate size of the plasmid was determined after comparison with *E. coli* 39R861 containing four plasmids of 147, 63, 36, and 7 kb.

Data analyses. The amount of in-feed antimicrobials consumed (in milligrams) to produce 1 kg of live chicken or pig was estimated from the concentration of antimicrobials in each feed product (as indicated on the label) and the feed conversion rate (FCR) (the amount of feed required to produce 1 kg of animal live weight). The FCR values used were 2.85 for chickens and 3.90 for pigs (22, 23). Since some feed products had ambiguous labeling (i.e., the manufacturer indicated that they contained one of two or more different antimicrobials), separate calculations were performed on the assumption that either of the listed antimicrobials was present.

The amount of antimicrobials administered by the farmer (i.e., excluding commercial medicated feeds) to produce 1 kg of live animal was estimated by dividing the total amount of each antimicrobial used (in milligrams) by the estimated body weight (in kilograms) of an animal at the end of its production cycle. Since weight data on chickens and pigs at slaughter were not available, we assumed that the weights of chickens and pigs raised for 2 months and 5 months were 1.5 kg and 92.5 kg, respectively (22, 23).

In order to explore the association between antimicrobial use and AMR, we calculated the Pearson's correlation coefficient between the quantities of antimicrobials used on each farm and the average number of antimicrobials to which *E. coli* isolates from those farms were resistant for chicken and pig farms separately. The potential association between the use (versus lack of use) of specific antimicrobials during periods 1 and 2 and the observed phenotypic and genotypic AMR (outcome) of isolates recovered on sampling visits 2 and 3 was investigated using univariable risk ratios (RR) for chicken and pig farms. In all cases, the baseline group

TABLE 1 Amounts of antimicrobials present in commercial feeds and estimated consumption of in-feed antimicrobials on each of the 9 farms investigated

Product no.	Period of use ^a	Antimicrobial	Concn of antimicrobial in feed (mg/kg live wt)	Estimated consumption of in-feed antimicrobials ^b								
				Chicken farms					Pig farms			
				C1	C3	C4	C5	C6	P2	P3	P5	P6
1	1 and 2	Avilamycin OR	10	28.5	28.5	28.5	57.0	28.5				
		Enramycin	10	28.5	28.5	28.5	57.0	28.5				
2	1 and 2	Enramycin	10		28.5	28.5	28.5					
3	1 and 2	Colistin ^c OR	180							702.0		
		Florfenicol OR	30							117.0		
		Kitazamycin OR	110							429.0		
		Tiamulin OR	120							468.0		
		Amoxicillin ^c	150							585.0		
4	1 and 2	Avilamycin OR	10							39.0		
		Kitasamycin OR	110							429.0		
		Tiamulin	120							468.0		
5	1 and 2	Tylosin OR	40								156.0	
		Enramycin OR	20								78.0	
		Colistin ^c	150								585.0	
6	1 and 2	Chlortetracycline OR	50								195.0	
		Neomycin ^c OR	65								253.5	
		Enramycin OR	20								78.0	
		Virginiamycin	10								39.0	
7	1 and 2	Chlortetracycline OR	50								95.0	
		Virginiamycin OR	10								39.0	
		Lincomycin	20								78.0	
8	1 and 2	Chlortetracycline OR	100									390.0
		Bacitracin	50									195.0
9	1	Tylosin OR	40									156.0
		Enramycin OR	20									78.0
		Amoxicillin ^c	300									1,170.0
10	1	Tylosin OR	40									156.0
		Enramycin OR	20									78.0
		Colistin ^c	150									585.0
11	1 and 2	Chlortetracycline OR	50									195.0
		Lincomycin OR	20									78.0
		Virginiamycin OR	10									39.0
		Enramycin	20									78.0

^a Period 1, early phase of production; period 2, late phase of production.

^b Details of antimicrobials in feed were not available for farms C2, P1, and P4.

^c Antimicrobial considered to be critically important for human medicine according to WHO criteria.

referred to the prevalence of AMR among isolates from farms that did not use antimicrobials in that period.

The agreement between phenotypic and genotypic resistances for ciprofloxacin, gentamicin, and colistin was determined using the kappa statistic (κ). Statistical analyses were performed using the epiCalc and epiR packages in R version 3.0.2 (R Foundation for Statistical Computing).

RESULTS

Farms and isolates. The six chicken farms ranged in size from 500 to 6,000 chickens (mean = 2,572; standard deviation [SD], $\pm 2,318$); the six pig farms ranged in size from 73 to 250 pigs

(mean = 108; SD, ± 61). We isolated a total of 180 *E. coli* strains (5 isolates/visit) during the routine farm visits.

Antimicrobials in commercial feed. All the farms used commercial feed. Totals of 4 and 13 different feed products were found on the chicken and pig farms, respectively. The identity of the feed product (and its antimicrobial composition) could be established for 3 of the chicken and 10 of the pig feed products. A total of two chicken and nine pig products contained at least one antimicrobial (Table 1). However, for 10/11 feed products, the label indicated that the product contained one (only one) of several antimicrobials listed (up to five).

TABLE 2 Amounts of antimicrobials administered for prophylactic and therapeutic purposes on chicken and pig farms^a

Antimicrobial class	Antimicrobial agent	Amt administered (mg/kg live wt)											
		Chicken farms						Pig farms					
		C1	C2	C3	C4	C5	C6	P1	P2	P3	P4	P5	P6
Aminoglycoside	Neomycin ^b							11.7					
	Kanamycin ^b									11.1			
	Gentamicin ^b					26.7			16.2	6.7		5.9	14.3
β-Lactam	Amoxicillin				40.0	13.3				25.1			22.3
	Ampicillin									17.8			
Cephalosporin	Cephalexin						5.6						
	Ceftiofur										9.5		
Macrolide	Tylosin	23.0						5.6		12.2			
	Tilmicosin		6.8	10.0									
	Spiramycin ^b									12.5			23.8
Phenicol	Chloramphenicol								6.5				
	Florfenicol		11.3	16.7								11.1	
Polypeptide	Colistin ^b				5.3	1.8					1.4		3.3
Fluoroquinolone	Enrofloxacin				66.7			11.1			23.3	19.1	40.6
	Norfloxacin ^b					53.3					1.8		4.9
Tetracycline	Doxycycline	46.0	5.6	8.3		26.7	5.6					5.5	
	Oxytetracycline							11.7					
Total		69.0	23.7	35.0	112.0	121.8	27.9	23.4	47.4	85.4	30.4	44.8	86.9

^a Each line represents one antimicrobial component.

^b Antimicrobial considered to be critically important for human medicine according to WHO criteria.

Totals of 2 and 13 different antimicrobials were listed for chicken and pig feed products, respectively. Enramycin and chlortetracycline were the most common antimicrobials present in pig feeds (in five and four products, respectively). Colistin, amoxicillin, and neomycin (all considered to be of critical importance by the WHO) were present in three, two, and one of the pig feed products investigated, respectively. No antimicrobials considered to be of critical importance by the WHO were present in any of the three chicken feeds. Pig feed was supplemented with antimicrobials at significantly higher concentrations (median, 45 mg/kg) than chicken feeds (median, 10 mg/kg) ($P < 0.001$). The median estimated amounts of in-feed antimicrobials used to produce 1 kg (live weight) of chicken and pig were 57.0 (interquartile range [IQR], 28.5 to 57.0) mg and 507.0 (IQR, 312.0 to 877.5) mg, respectively.

Antimicrobials administered for prophylactic and therapeutic purposes. In addition to antimicrobials present in feed, all the chickens and pigs were administered antimicrobials by the farmer at least once in their life cycles. Totals of 10 and 15 different antimicrobial products were used on chicken and pig farms, respectively. Fifty percent of the chicken products and 66.7% of the pig products contained two or more antimicrobial compounds among their ingredients. A total of 17 different antimicrobials belonging to eight classes were identified (Table 2). Three chicken products and nine pig products contained antimicrobials considered to be of critical importance for human medicine (neomycin, kanamycin, gentamicin, spiramycin, colistin, and norfloxacin).

On chicken farms, antimicrobials were administered for pre-

vention of disease in 11 (73.3%) instances and for treatment (of respiratory disease) on four occasions (26.7%). On pig farms, antimicrobials were administered for treatment of respiratory and enteric disease in 18 (66.7%) instances, in 4 (14.8%) instances for disease prevention, and in 5 (18.5%) instances for both purposes. On chicken farms, antimicrobials were administered using water (100% of cases), whereas antimicrobials were administered by injection (93.3% of cases) on pig farms.

The estimated amounts of antimicrobials administered per kilogram of live weight were 52.0 (IQR, 29.7 to 101.2) mg and 46.1 (IQR, 34.0 to 75.9) mg for chickens and pigs, respectively.

Phenotypic testing for AMR among *E. coli* isolates. The highest prevalence of resistance to specific antimicrobials among *E. coli* isolates was to ampicillin (97.8% and 94.4% for chickens and pigs, respectively), followed by ciprofloxacin (73.3% and 21.1%), gentamicin (42.2% and 35.6%), colistin (22.2% and 24.4%), and ceftazidime (1.1% and 7.8%) (Fig. 1). The overall prevalence of MDR (defined here as resistance to at least three classes of antimicrobials) among chicken isolates was significantly higher than that among the organisms isolated from pigs (43.3% versus 24.4%, respectively) ($P = 0.01$; Fisher's exact test).

Organisms isolated from chickens exhibited a significantly higher prevalence of resistance to gentamicin at the middle and end of production combined (51.7%) than on the day of arrival (23.3%) ($P = 0.02$; Fisher's exact test). Organisms isolated from pigs exhibited a higher prevalence of colistin resistance at midproduction than at farrowing (36.6% versus 3.3%) ($P = 0.002$; Fisher's exact test). Compared with midproduction, pig




FIG 1 Prevalence of AMR among 180 *E. coli* isolates (30 isolates/visit/host species) from 12 farms in Tien Giang, Vietnam (2013–2014). The error bars indicate 95% confidence intervals. AMP, ampicillin; CAZ, ceftazidime; CIP, ciprofloxacin; CN, gentamicin; CT, colistin.

isolates from the end of production had a significantly decreased prevalence of resistance to ciprofloxacin (33.3% versus 6.7%) and gentamicin (50.0% versus 20.0%) and a lower rate of MDR isolates (40.0% versus 10.0%) ($P < 0.03$ in all cases; Fisher's exact test).

PCR screening for AMR-associated genes. Quinolone resistance in *E. coli* is determined predominantly by mutations at codons 83 and 87 in the *gyrA* gene. A total of 33.3% of chicken isolates and 18.3% of pig isolates had a single mutation in the *gyrA* gene. Double mutations were found in 43.3% of chicken isolates and 13.3% of pig isolates. A total of 24.4% of chicken and 11.1% of pig *E. coli* isolates produced amplicons for the PMQR gene *qnrA*;

23.3% of chicken isolates and 43.3% of pig isolates were positive for *qnrS*. We detected the *aac(6')-Ib-cr* gene in two pig isolates. None of the isolates from chicken or pig harbored either the *qnrB* or the *qepA* gene (Fig. 2). Isolates from chickens had a higher prevalence of *gyrA* double mutations ($P < 0.001$; Fisher's exact test) and *qnrA* ($P = 0.03$; Fisher's exact test) than isolates from pigs. In contrast, isolates from pigs had a higher prevalence of the *qnrS* gene than isolates from chickens ($P = 0.007$; Fisher's exact test). Among the organisms isolated from pigs, the prevalence of double mutations in the *gyrA* gene was higher among isolates from midproduction (26.6%) than among the isolates from the end of production (3.3%) ($P = 0.03$; Fisher's exact test). There was no




FIG 2 Prevalence of antimicrobial resistance genes among 180 *E. coli* isolates recovered from 12 farms in Tien Giang, Vietnam (2013–2014). *, phenotypic prevalence of antimicrobial resistance. (1), single mutation; (2), double mutation. The error bars indicate the 95% CI.

TABLE 3 Estimation of the level of agreement between resistance phenotypes and genotypes in *E. coli* isolates

Antimicrobial	Gene(s) carried	Chicken ^a						Pig ^a					
		κ	a	b	c	d	P value	κ	a	b	c	d	P value
Ciprofloxacin	<i>qnrA</i>	0.07	20	48	4	18	0.150	-0.07	2	17	8	63	0.835
	<i>qnrB</i>	NC	0	66	0	24	NC	NC	0	19	0	71	NC
	<i>qnrS</i>	0.02	19	50	5	16	0.368	0.12	6	13	33	38	0.127
	<i>aac(6′)-Ib-cr</i>	NC	0	66	0	24	NC	0.15	2	17	0	71	0.055
	<i>qepA</i>	NC	0	66	0	24	NC	NC	0	19	0	71	NC
	<i>gyrA</i> _{single}	0.01	22	44	8	16	0.50	0.24	7	12	10	61	0.012
	<i>gyrA</i> _{double}	0.43	39	27	0	24	<0.001	0.73	12	7	0	71	<0.001
Gentamicin	<i>aadA</i>	0.33	28	11	18	33	<0.001	0.13	29	3	43	15	0.030
	<i>strA-strB</i>	0.26	26	13	17	34	<0.001	0.19	10	22	8	50	0.011
Colistin	<i>mcr-1</i>	1.0	20	0	0	70	<0.001	0.84	17	5	0	68	<0.001

^a a, positive genotype, positive phenotype; b, negative genotype, positive phenotype; c, positive genotype, negative phenotype; d, negative genotype, negative phenotype; NC, not calculated.

difference in the prevalence of PMQR determinants between different stages of production.

The prevalence of the *aadA* gene (encoding aminoglycoside resistance) was higher among pig isolates (80.0%) than among chicken isolates (51.1%) ($P < 0.001$; Fisher’s exact test). In contrast, the prevalence of the *strA-strB* genes was lower in pig isolates (20.0%) than in chicken isolates (47.8%) ($P = 0.001$; Fisher’s exact test). The prevalence of *strA-strB* was higher among chicken isolates from midproduction (60.0%) than among isolates from 1-day-old chicks (26.7%) ($P = 0.02$; Fisher’s exact test). In contrast, no changes in the prevalence of *strA-strB* was observed between the stages of pig production.

The prevalences of the recently discovered plasmid-mediated colistin resistance gene *mcr-1* were 18.9% and 22.2% in pig and chicken *E. coli* isolates, respectively (Fig. 2). The prevalence of *mcr-1* did not change significantly during the production cycle. Among 20 and 17 *mcr-1*-positive *E. coli* isolates from chickens and pigs, respectively, colistin resistance could be successfully transferred by conjugation in 70.0% and 35.3% of the isolates. The estimated transfer frequency in successful experiments was 10^{-1} to 10^{-3} cells per donor cell. All transconjugants acquired one plasmid approximately 63 kb in size. Furthermore, 7 of the 20 transconjugants contained additional plasmids that were <63 kb or >100 kb in size.

Relationship between phenotypic and genotypic resistance. Double mutations in the *gyrA* gene exhibited the highest agreement with ciprofloxacin resistance for both chicken and pig isolates ($\kappa = 0.43$ and 0.73 , respectively) (Table 3). A single *gyrA* mutation was associated with low levels of resistance to ciprofloxacin (median MIC, 3 [IQR, 1.0 to 32] $\mu\text{g/ml}$ in chicken and 0.75 [IQR, 0.19 to 3] $\mu\text{g/ml}$ in pig isolates), and double mutations were associated with high levels of resistance (median MIC, 32 $\mu\text{g/ml}$ [IQR, 24 to 32 $\mu\text{g/ml}$ and 4 to 16 $\mu\text{g/ml}$ for chicken and pig isolates, respectively]). Amplification of PMQR had a lower agreement with phenotypic ciprofloxacin resistance ($\kappa < 0.2$) in all isolates from chickens and pigs.

Among the *E. coli* organisms isolated from chickens, the presence of *aadA* and *strA-strB* exhibited a reasonable agreement with gentamicin resistance ($\kappa = 0.33$ and 0.26 , respectively) (Table 3). Among pig isolates, the presence of *strA-strB* had the strongest agreement with gentamicin resistance ($\kappa = 0.19$).

The presence of *mcr-1* had very strong agreement with colistin resistance in both chicken ($\kappa = 1.0$) and pig ($\kappa = 0.84$) isolates. Among the *mcr-1*-positive strains, the median MIC of colistin was 4 $\mu\text{g/ml}$ (IQR, 3 to 4 $\mu\text{g/ml}$ and 4 to 6 $\mu\text{g/ml}$ for chicken and pig isolates, respectively).

Association between antimicrobial use and antimicrobial resistance. We found no correlation between total use of antimicrobials at the farm level and AMR (calculated as the average number of antimicrobials against which *E. coli* isolates were resistant) ($P > 0.83$). However, the use of quinolones and cephalosporins in the period between birth and midproduction was statistically associated with ciprofloxacin resistance (RR = 9.0 and 5.0, respectively) and colistin resistance (RR = 11.0 and 4.17, respectively) in midproduction on pig farms (Table 4). Cephalosporin use in the first period of production was strongly associated with detection of the *strA-strB* genes in isolates from the second sampling (RR = 5.0). Mutations in *gyrA* among *E. coli* isolates were strongly associated with the use of phenicols (RR = 20.0), tetracyclines (RR = 10.0), and β -lactams (RR = 5.0) throughout the whole production cycle and with the use of quinolones (RR = 4.5) and cephalosporins (RR = 4.17) in the first period. No association between antimicrobial use and resistance was observed on chicken farms.

DISCUSSION

There are very few published longitudinal studies quantifying AMU and describing AMR in poultry and pigs in developing countries (3, 4). Our work represents an important contribution toward understanding the interplay between AMU and AMR on farms in Southeast Asia.

Our results indicate that comparable quantities of antimicrobials were administered by farmers to produce chicken meat and pig meat (52.0 mg per kg live weight versus 46.1 mg, respectively). However, consumption of antimicrobials in feed was considerably higher in pigs than in chickens, resulting in overall greater amounts of antimicrobials consumed by pigs (563.6 mg per kg live weight) than chickens (94.7 mg per kg live weight). Critically important medicines for humans, such as colistin, neomycin, gentamicin, kanamycin, and norfloxacin, were also used on the studied farms. On pig farms, a median of 3 (out of 8) critical antimicrobials were used to raise the animals. A previous study in Vietnam showed much larger amounts of antimicrobials were adminis-

TABLE 4 Associations between antimicrobial use and phenotypic and genotypic resistance among *E. coli* isolates from pigs

Exposure	No. of farms using antimicrobial	Outcome ^a	RR ^b	95% CI ^c	P value
Exposure, antimicrobial use in period 1; outcome, resistance in second sampling					
Quinolones	3	CT	11.0	2.71–44.66	<0.001
Cephalosporins	1	CT	4.17	1.49–11.71	0.007
Quinolones	3	CIP	9.0	1.84–44.07	0.007
Cephalosporins	1	CIP	5.0	1.71–14.6	0.003
Cephalosporins	1	<i>strA-strB</i>	5.0	1.34–18.61	0.016
Quinolones	3	<i>gyrA</i> ^d	4.50	1.23–16.46	0.023
Cephalosporins	1	<i>gyrA</i> ^d	4.17	1.49–11.71	0.007
Exposure, antimicrobial use over whole production period; outcome, resistance in third sampling					
Tetracyclines	1	<i>gyrA</i> ^d	10.0	2.71–36.96	<0.001
β-Lactams	2	<i>gyrA</i> ^d	5.0	1.02–24.52	0.047
Phenicol	1	<i>gyrA</i> ^d	20.0	4.38–91.42	<0.001

^a CIP, ciprofloxacin; CT, colistin.

^b Only significant ($P < 0.05$) risk ratios are presented.

^c CI, confidence interval.

^d Single or double mutation.

tered by farmers on meat chicken farms (470.4 mg per chicken produced, equivalent to 276.7 mg per kg, assuming an average weight of 1.7 kg) (6). These differences may reflect management practices related to intensification of farming systems. In this study, farms were much larger (mean, 2,572 chickens per farm), whereas in our previous study, all the farms had <2,000 chickens. The same study showed that larger production units used up to five times less antimicrobials per time unit than smaller units (6). Antimicrobials administered to chickens were mostly used to prevent disease (73.3%); in contrast, most antimicrobials administered to pigs were used for disease treatment (66.7%). Chickens were often administered antimicrobials through water or feed, whereas pigs were administered antimicrobials mostly through injection. This may have resulted in higher levels of AMR in the gastrointestinal microbiota in the chicken species.

We found higher prevalences of resistance to ciprofloxacin and gentamicin among *E. coli* isolates than those in previous studies in the region (73.3% and 42.2% compared to 21.0 to 24.2% and 10.8 to 15.0%, respectively) (7, 11). Our results show that mutations in the *gyrA* sequence play a key role in the development of resistance to quinolone antimicrobials, whereas the PMQR-associated mechanisms investigated appeared to be less common (12, 24). The presence of both *aadA* and *strA-strB* was most commonly associated with gentamicin resistance in chickens and pigs, respectively. Published studies have shown an association between these genes and resistance to streptomycin and other aminoglycosides among *E. coli* isolates from poultry and pigs (25, 26).

A particular concern is the high prevalence (22% to 25%) of colistin (a polymyxin antimicrobial) resistance among pig and chicken *E. coli* isolates. Colistin is regarded as a last-line antimicrobial for the treatment of severe human infection cause by MDR Gram-negative bacteria. Historically most colistin resistance mechanisms have involved chromosomal mutations (27). More recently, studies from Europe and Asia have reported the emergence of the *mcr-1* gene in *Enterobacteriaceae* of chicken and pig origins (15, 28, 29). Our results indicated a prevalence of the plasmid-mediated *mcr-1* gene in *E. coli* isolates similar to those re-

ported in the Chinese study. We also observed very strong agreement between colistin phenotypic resistance and the presence of the *mcr-1* gene in both chicken and pig isolates. The plasmids containing the *mcr-1* gene were of similar size (~63 kb) to those reported in China (15) and showed a very high *in vitro* transfer rate between *E. coli* strains. These results suggest that this *mcr-1*-containing plasmid is probably widespread globally by now. Our findings indicated that colistin is commonly used on chicken and pig farms (on 4/12 farms as a prophylactic/therapeutic drug), as well as potentially in feed on 3 pig farms, as has been shown in previous studies in Vietnam (6, 8). We did not, however, observe an increased prevalence of colistin resistance among the four farms where the farmers had administered colistin. In addition, ~20% of the isolates from 1-day-old chicks tested positive, suggesting vertical transmission from breeder flocks and the capacity of colistin-resistant strains to survive the hatchery process. Given the ambiguous labeling of the feed products with regard to their antimicrobial contents, it is not possible to determine whether colistin was also used in the feed on three other farms. Our findings suggest that the use of quinolones and cephalosporins may select for colistin resistance in pigs, although the reasons for this are currently unknown.

Our results reflect the complexity of AMR and the difficulties in accurately establishing the specific genetic mechanisms underlying specific types of AMR due to the multitude of potential genetic mechanisms. Especially in the cases of colistin (the *mcr-1* gene) and quinolones (*gyrA* gene mutations), we believe that the genetic mechanisms identified are likely to make major contributions to AMR to those compounds. In contrast, the genes assayed (*aadA* and *strA-strB* genes) seemed to have made a smaller contribution to gentamicin resistance.

We did not find an overall relationship between total antimicrobial use and AMR on farms. In contrast, we found some unexplained univariable relationships between the use of certain antimicrobials and certain phenotypic and genotypic AMR patterns on pig farms. This has to be interpreted with caution, especially given the relatively small sample size of our study (6 chicken and 6

pig farms), all subjected to considerable AMR selection pressure, and the potential existence of confounding factors that were not included in the analyses. Unfortunately, the fact that on all the farms antimicrobials were used intensively (i.e., no negative controls were available) makes it difficult to elucidate this relationship. Also, on all the farms, antimicrobials were present in commercial feeds, but it was not possible to determine exactly which antimicrobials are likely to confound this association. In addition, AMR bacteria may also be acquired from external sources and potentially transfer to current animals from animals kept in the building during the previous cycle, (carryover). Because of the impossibility of anticipating the behavior of farmers, we believe that such studies should preferably be performed in experimental-farm settings, where antimicrobial exposure (i.e., quinolones and macrolides) is well controlled.

Among *E. coli* isolates from pigs, lower prevalences of AMR (for ciprofloxacin and gentamicin) and MDR were found in finishers than in younger pigs. It has been suggested that this may be a reflection of the fitness cost of resistant organisms in the intestinal tract (30). For chickens, an overall lower prevalence of AMR and MDR was found among chicks sampled on arrival at the farm, and an increase was detected for all antimicrobials during production. However, levels of full resistance to ciprofloxacin and ampicillin in 1-day-old chicks were particularly high (46.7% and 36.7%, respectively). Unfortunately, information about potential antimicrobial use in hatcheries was not gathered. On poultry farms, resistant bacteria may be introduced through vertical transmission from parental flocks or contamination in the hatchery environment (31). The presence of resistance in newborn piglets is likely to reflect lateral transmission from the sows (32). In addition to AMU, husbandry practices, inadequate cleaning and disinfection, and the types of feed used may all contribute to AMR (7, 32).

In spite of the small sample size (12 farms), our study provides accurate baseline information on AMU, as well as on the dynamics of phenotypic and genotypic resistance among *E. coli* isolates over the different stages of production in emerging pig and poultry production systems in southern Vietnam. We recommend that future research focus on the simultaneous detection of large numbers of AMR genes of greater concern, especially those coding for resistance to critically important antimicrobials that are carried on mobile genetic elements. We also recommend that longitudinal studies capture quantitative changes in the resistome in the sample matrix (as opposed to individual colonies). Although such technologies are currently very costly, they will probably become affordable in the near future. *E. coli* showed a high prevalence of resistance to a last-line antimicrobial (colistin), as well as antimicrobials (ciprofloxacin and gentamicin) critically important for human medicine. We strongly recommend that these important antimicrobials be restricted to treatment of clinical disease and not be used for prophylaxis.

ACKNOWLEDGMENTS

We thank the staff of the Tien Giang Sub-Department of Animal Health for their support for sample collection. We also thank Pham Thanh Duy and Nguyen To Nguyen (OUCRU) for help with plasmid conjugation experiments.

We declare that we have no competing interests.

FUNDING INFORMATION

This work, including the efforts of Nhung Thi Nguyen, Hoa Mai Nguyen, Cuong Van Nguyen, Trung Vinh Nguyen, Men Thi Nguyen, Hieu Quoc Thai, Mai Huynh Ho, Guy Thwaites, and Hoa Thi Ngo, was funded by Wellcome Trust (089276/Z/09/Z). This work, including the efforts of Stephen Baker, was funded by Wellcome Trust (100087/Z/12/Z). This work, including the efforts of Juan Jose Carrique-Mas, was funded by Wellcome Trust (110085/Z/15/Z).

REFERENCES

1. Pagel SW, Gautier P. 2012. Use of antimicrobial agents in livestock. *Rev Sci Tech* 31:145–188. <http://dx.doi.org/10.20506/rst.31.1.2106>.
2. FAO. 2007. Joint FAO/WHO/OIE expert meeting on critically important antimicrobials. Food and Agriculture Organization of the United Nations, Rome, Italy. <http://www.oie.int/doc/ged/D6289.PDF>.
3. Simoneit C, Burow E, Tenhagen BA, Kasbohrer A. 2015. Oral administration of antimicrobials increase antimicrobial resistance in *E. coli* from chicken—a systematic review. *Prev Vet Med* 118:1–7. <http://dx.doi.org/10.1016/j.prevetmed.2014.11.010>.
4. Burow E, Simoneit C, Tenhagen BA, Kasbohrer A. 2014. Oral antimicrobials increase antimicrobial resistance in porcine *E. coli*—a systematic review. *Prev Vet Med* 113:364–375. <http://dx.doi.org/10.1016/j.prevetmed.2013.12.007>.
5. WHO. 2012. Critically important antimicrobials for human medicine. WHO, Geneva, Switzerland. http://apps.who.int/iris/bitstream/10665/77376/1/9789241504485_eng.pdf.
6. Carrique-Mas JJ, Trung NV, Hoa NT, Mai HH, Thanh TH, Campbell JJ, Wagenaar JA, Hardon A, Hieu TQ, Schultz C. 2015. Antimicrobial usage in chicken production in the Mekong Delta of Vietnam. *Zoonoses Public Health* 62(Suppl 1):S70–S78. <http://dx.doi.org/10.1111/zph.12165>.
7. Nguyen VT, Carrique-Mas JJ, Ngo TH, Ho HM, Ha TT, Campbell JJ, Nguyen TN, Hoang NN, Pham VM, Wagenaar JA, Hardon A, Thai QH, Schultz C. 2015. Prevalence and risk factors for carriage of antimicrobial-resistant *Escherichia coli* on household and small-scale chicken farms in the Mekong Delta of Vietnam. *J Antimicrob Chemother* 70:2144–2152. <http://dx.doi.org/10.1093/jac/dkv053>.
8. Dang PK, Saegerman C, Douny C, Ton VD, Bo HX, Binh DV, Ngan HP, Scippo ML. 2013. First survey on the use of antibiotics in pig and poultry production in the Red River Delta region of Vietnam. *Food Public Health* 3:247–256. <http://dx.doi.org/10.5923/j.fph.20130305.03>.
9. Tadesse DA, Zhao S, Tong E, Ayers S, Singh A, Bartholomew MJ, McDermott PF. 2012. Antimicrobial drug resistance in *Escherichia coli* from humans and food animals, United States, 1950–2002. *Emerg Infect Dis* 18:741–749. <http://dx.doi.org/10.3201/eid1805.111153>.
10. Moyaert H, de Jong A, Simjee S, Thomas V. 2014. Antimicrobial resistance monitoring projects for zoonotic and indicator bacteria of animal origin: common aspects and differences between EASSA and EFSA. *Vet Microbiol* 171:279–283. <http://dx.doi.org/10.1016/j.vetmic.2014.02.038>.
11. Nhung NT, Cuong NV, Campbell J, Hoa NT, Bryant JE, Truc VN, Kiet BT, Jombart T, Trung NV, Hien VB, Thwaites G, Baker S, Carrique-Mas J. 2015. High levels of antimicrobial resistance among *Escherichia coli* isolates from livestock farms and synanthropic rats and shrews in the Mekong Delta of Vietnam. *Appl Environ Microbiol* 81:812–820. <http://dx.doi.org/10.1128/AEM.03366-14>.
12. Yue L, Jiang HX, Liao XP, Liu JH, Li SJ, Chen XY, Chen CX, Lu DH, Liu YH. 2008. Prevalence of plasmid-mediated quinolone resistance qnr genes in poultry and swine clinical isolates of *Escherichia coli*. *Vet Microbiol* 132:414–420. <http://dx.doi.org/10.1016/j.vetmic.2008.05.009>.
13. Ruiz E, Saenz Y, Zarazaga M, Rocha-Gracia R, Martinez-Martinez L, Arlet G, Torres C. 2012. qnr, aac(6′)-Ib-cr and qepA genes in *Escherichia coli* and *Klebsiella* spp.: genetic environments and plasmid and chromosomal location. *J Antimicrob Chemother* 67:886–897. <http://dx.doi.org/10.1093/jac/dkr548>.
14. Garcia-Migura L, Sunde M, Karlsmose S, Veldman K, Schroeter A, Guerra B, Granier SA, Perrin-Guyomard A, Gicquel-Bruneau M, Franco A, Englund S, Teale C, Heiska H, Clemente L, Boerlin P, Moreno MA, Daignault D, Mevius D, Hendriks RS, Aarestrup FM. 2012. Establishing streptomycin epidemiological cut-off values for *Salmonella* and *Escherichia coli*. *Microb Drug Resist* 18:88–93. <http://dx.doi.org/10.1089/mdr.2011.0064>.
15. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, Doi Y, Tian G,

- Dong B, Huang X, Yu LF, Gu D, Ren H, Chen X, Lv L, He D, Zhou H, Liang Z, Liu JH, Shen J. 2016. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. *Lancet Infect Dis* 16:161–168. [http://dx.doi.org/10.1016/S1473-3099\(15\)00424-7](http://dx.doi.org/10.1016/S1473-3099(15)00424-7).
16. CLSI. 2014. Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement. CLSI/NCCLS M100–S24. Clinical and Laboratory Standards Institute, Wayne, PA.
 17. EUCAST. 2015. Breakpoint tables for interpretation of MICs and zone diameters. European Committee on Antimicrobial Susceptibility Testing, Växjö, Sweden.
 18. Le TM, Baker S, Le TP, Cao TT, Tran TT, Nguyen VM, Campbell JI, Lam MY, Nguyen TH, Nguyen VV, Farrar J, Schultz C. 2009. High prevalence of plasmid-mediated quinolone resistance determinants in commensal members of the Enterobacteriaceae in Ho Chi Minh City, Vietnam. *J Med Microbiol* 58:1585–1592. <http://dx.doi.org/10.1099/jmm.0.010033-0>.
 19. Tamang MD, Oh JY, Seol SY, Kang HY, Lee JC, Lee YC, Cho DT, Kim J. 2007. Emergence of multidrug-resistant *Salmonella enterica* serovar Typhi associated with a class 1 integron carrying the *dfrA7* gene cassette in Nepal. *Int J Antimicrob Agents* 30:330–335. <http://dx.doi.org/10.1016/j.ijantimicag.2007.05.009>.
 20. Madsen L, Aarestrup FM, Olsen JE. 2000. Characterisation of streptomycin resistance determinants in Danish isolates of *Salmonella* Typhimurium. *Vet Microbiol* 75:73–82. [http://dx.doi.org/10.1016/S0378-1135\(00\)00207-8](http://dx.doi.org/10.1016/S0378-1135(00)00207-8).
 21. Kado CI, Liu ST. 1981. Rapid procedure for detection and isolation of large and small plasmids. *J Bacteriol* 145:1365–1373.
 22. Tiên PD, Điều ND. 2012. Farming techniques: high productivity and quality of Luong Phuong chicken production, p 8–9. Agricultural Publisher, National Research Institute of Animal Science, Hanoi, Vietnam.
 23. Tiệp PS. 2008. Pig production techniques. Labour and Social Publisher, National Research Institute of Animal Science, Ministry of Agriculture and Rural Development, Hanoi, Vietnam. http://vcn.vnn.vn/scn_tiep2008_vcn_d184_dg42.aspx. (In Vietnamese.)
 24. Liu BT, Liao XP, Yang SS, Wang XM, Li LL, Sun J, Yang YR, Fang LX, Li L, Zhao DH, Liu YH. 2012. Detection of mutations in the *gyrA* and *parC* genes in *Escherichia coli* isolates carrying plasmid-mediated quinolone resistance genes from diseased food-producing animals. *J Med Microbiol* 61:1591–1599. <http://dx.doi.org/10.1099/jmm.0.043307-0>.
 25. Rosengren LB, Waldner CL, Reid-Smith RJ. 2009. Associations between antimicrobial resistance phenotypes, antimicrobial resistance genes, and virulence genes of fecal *Escherichia coli* isolates from healthy grow-finish pigs. *Appl Environ Microbiol* 75:1373–1380. <http://dx.doi.org/10.1128/AEM.01253-08>.
 26. Sunde M, Norstrom M. 2006. The prevalence of, associations between and conjugal transfer of antibiotic resistance genes in *Escherichia coli* isolated from Norwegian meat and meat products. *J Antimicrob Chemother* 58:741–747. <http://dx.doi.org/10.1093/jac/dkl294>.
 27. Cannatelli A, D'Andrea MM, Giani T, Di Pilato V, Arena F, Ambretti S, Gaibani P, Rossolini GM. 2013. In vivo emergence of colistin resistance in *Klebsiella pneumoniae* producing KPC-type carbapenemases mediated by insertional inactivation of the PhoQ/PhoP mgrB regulator. *Antimicrob Agents Chemother* 57:5521–5526. <http://dx.doi.org/10.1128/AAC.01480-13>.
 28. Malhotra-Kumar S, Xavier BB, Das AJ, Lammens C, Hoang HT, Pham NT, Goossens H. 2016. Colistin-resistant *Escherichia coli* harbouring *mcr-1* isolated from food animals in Hanoi, Vietnam. *Lancet Infect Dis* 16:286–287. [http://dx.doi.org/10.1016/S1473-3099\(16\)00014-1](http://dx.doi.org/10.1016/S1473-3099(16)00014-1).
 29. Perrin-Guyomard A, Bruneau M, Houee P, Deleurme K, Legrandois P, Poirier C, Soumet C, Sanders P. 2016. Prevalence of *mcr-1* in commensal *Escherichia coli* from French livestock, 2007 to 2014. *Euro Surveill* 21. <http://dx.doi.org/10.2807/1560-7917.ES.2016.21.6.30135>.
 30. Marchant M, Moreno MA. 2013. Dynamics and diversity of *Escherichia coli* in animals and system management of the manure on a commercial farrow-to-finish pig farm. *Appl Environ Microbiol* 79:853–859. <http://dx.doi.org/10.1128/AEM.02866-12>.
 31. Baron S, Jouy E, Larvor E, Eono F, Bougeard S, Kempf I. 2014. Impact of third-generation-cephalosporin administration in hatcheries on fecal *Escherichia coli* antimicrobial resistance in broilers and layers. *Antimicrob Agents Chemother* 58:5428–5434. <http://dx.doi.org/10.1128/AAC.03106-14>.
 32. Callens B, Faes C, Maes D, Catry B, Boyen F, Francoys D, de Jong E, Haesebrouck F, Dewulf J. 2015. Presence of antimicrobial resistance and antimicrobial use in sows are risk factors for antimicrobial resistance in their offspring. *Microb Drug Resist* 21:50–58. <http://dx.doi.org/10.1089/mdr.2014.0037>.